Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A benign or malignant paraganglioma arising from the chromaffin cells of the paraganglia that are located along the sympathetic nerves. It includes extra-adrenal paragangliomas and paragangliomas that arise from the adrenal medulla. The latter are commonly referred to as pheochromocytomas. Representative examples of extra-adrenal sympathetic paragangliomas include the bladder, and superior and inferior paraaortic paragangliomas. Clinical signs are related to the secretion of catecholamines resulting in hypertension.
Biomarker and diagnostic research for sympathetic paraganglioma has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
85 publications have been identified in PubMed for sympathetic paraganglioma. Research spans Case Report / Case Series (47%), Basic Science / Preclinical (20%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 40 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 4:30 PM UTC
Laboratory research | 17 | 20% |
Research summaries | 16 | 19% |
Testing and diagnosis research | 5 | 6% |
Clinical study results | 3 | 4% |
Disease patterns and progression | 2 | 2% |
New treatment approaches | 2 | 2% |
Alesina PF (2026). [PMID: 41697281](https://pubmed.ncbi.nlm.nih.gov/41697281/). *Chirurgie (Heidelb)*. [Review / Meta-Analysis]
Angelousi A (2026). [PMID: 42171133](https://pubmed.ncbi.nlm.nih.gov/42171133/). *Endocr Relat Cancer*. [Review / Meta-Analysis]
Tamayo Y (2026). [PMID: 41193899](https://pubmed.ncbi.nlm.nih.gov/41193899/). *Abdom Radiol (NY)*. [Case Report / Case Series]
Madu AC (2026). [PMID: 42216610](https://pubmed.ncbi.nlm.nih.gov/42216610/). *Br J Hosp Med (Lond)*. [Case Report / Case Series]
Wang X (2026). [PMID: 42074262](https://pubmed.ncbi.nlm.nih.gov/42074262/). *Int J Mol Sci*. [Basic Science / Preclinical]
Al Khazal FJ (2026). [PMID: 42181244](https://pubmed.ncbi.nlm.nih.gov/42181244/). *iScience*. [Gene Therapy / Novel Therapeutics]
Mitchell F (2026). [PMID: 41886882](https://pubmed.ncbi.nlm.nih.gov/41886882/). *J Comp Pathol*. [Case Report / Case Series]
Shekhda KM (2026). [PMID: 41945626](https://pubmed.ncbi.nlm.nih.gov/41945626/). *Arch Endocrinol Metab*. [Case Report / Case Series]
Miltenburg JB (2026). [PMID: 41404848](https://pubmed.ncbi.nlm.nih.gov/41404848/). *Endocrine-related cancer*. [Case Report / Case Series]
Zhang J (2026). [PMID: 41881005](https://pubmed.ncbi.nlm.nih.gov/41881005/). *Exp Clin Endocrinol Diabetes*. [Clinical Trial Publication]